Results 71 to 80 of about 26,025 (223)

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Abstract Background Real‐world data are an essential complement to clinical trials. This is particularly true for chronic lymphocytic leukemia, where five first‐line options have never been directly compared. Methods The authors present the results of a national multicenter real‐world study focusing on treatment choices in frontline chronic lymphocytic
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +2 more sources

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis [PDF]

, 2017
The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies.
Butterworth, Michael, Byrne, Dominic P, Cohen, Gerald M, Eyers, Patrick A, Greaves, Georgia, Milani, Mateus, Varadarajan, Shankar   +6 more
core   +2 more sources

CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator

Cell Death and Disease
BCL-2 inhibitors such as venetoclax offer therapeutic promise in acute myeloid leukemia (AML) and other cancers, but drug resistance poses a significant challenge. It is crucial to understand the mechanisms that regulate venetoclax response.
Lixia Zhang, Xinyue Zhou, Sajesan Aryal, Virginia Veasey, Pengcheng Zhang, Fu Jun Li, Yu Luan, Ravi Bhatia, Yang Zhou, Rui Lu   +9 more
doaj   +1 more source

Current perspectives in fragment based lead discovery (FBLD) [PDF]

, 2017
It is over 20 years since the first fragment-based discovery projects were disclosed. The methods are now mature for most ‘conventional’ targets in drug discovery such as enzymes (kinases and proteases) but there has also been growing success on more ...
Alvarez-Garcia, Bas Lamoree, Baurin, Bertrand, Boehm, Bollag, Chen, Chen, Congreve, Darby, Davies, English, Erlanson, Erlanson, Erlanson, Fischer, Giannetti, Goodford, Gossert, Hajduk, Hajduk, Hajduk, Hann, Hopkins, Howard, Hubbard, Hubbard, Hubbard, Hubbard, Jencks, Johnson, Keseru, Kozakov, Lau, Linke, Ludlow, Maurer, Meiby, Miller, Miranker, Nasiri, Nienaber, Oltersdorf, Ostrem, Parker, Paul Workman, Pearce, Renaud, Ringe, Rob L.M. van Montfort, Roderick E. Hubbard, Roughley, Ruiz-Carmona, Schiebel, Schiebel, Schulz, Shuker, Souers, Sun, Vivat   +59 more
core   +1 more source

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

British Journal of Haematology, EarlyView.
Summary Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL).
David J. Allsup, David A. Cairns, E. Faye Samy, Lelia Duley, Adrian Bloor, Abraham Varghese, David Meads, Bryony Dawkins, Sean Girvan, Dena R. Howard, Anna Hockaday, Julia M. Brown, Sharon Jackson, Natasha Greatorex, Phoebe Templeton, Michael Tupper, David Phillips, Sonam Yaqub, Di Mortimer, David Stones, Piers E. M. Patten, Andrew Rawstron, Peter Hillmen, Talha Munir   +23 more
wiley   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

Hot-spot analysis for drug discovery targeting protein-protein interactions [PDF]

, 2018
Introduction: Protein-protein interactions are important for biological processes and pathological situations, and are attractive targets for drug discovery. However, rational drug design targeting protein-protein interactions is still highly challenging.
Fernández-Recio, Juan, Rosell, Mireia
core   +2 more sources

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

American Journal of Hematology, EarlyView.
Jennifer A. Woyach, Relja Popovic, Emily L. Rossi, Sanjana Singh, Toshihiko Oki, Tanya S. Rosenberg, Chen Qian, Michael Moran, Zihuan Liu, Michelle Boyer, Jeffrey Jones, Richard R. Furman, William Wierda, Jason Gotlib, Stephen J. Schuster, Brenda Chyla, Matthew S. Davids   +16 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Haematologica, 2018
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia ...
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan   +47 more
doaj   +1 more source